Descriptive statistics of groups used for survival analyses (data set B)
| AZA | GLAT | IFN | Mitox | RTX | p Value | |
| Treatments | ||||||
| Patient-years, sum | 63.3 | 10.3 | 61.2 | 30.5 | 96.2 | |
| Episodes, n (%) | 67 (20.8) | 28 (8.7) | 74 (23) | 48 (14.9) | 105 (32.6) | <0.001 |
| Attack-free episodes, n (%) | 47 (70.1) | 16 (57.1) | 30 (40.5) | 30 (62.5) | 68 (64.8) | 0.07 |
| No previous attack under same therapy, n (%) | 49 (73.1) | 17 (60.7) | 30 (40.5) | 32 (66.7) | 70 (66.7) | 0.001 |
| First-line therapy, n (%) | 41 (24.7) | 14 (8.4) | 60 (36.1) | 25 (15.1) | 26 (16.0) | <0.001 |
| Dose, mean (SD) | 128 (44.5) mg/day | 20 mg/day | Various | 11.4 (1.0) mg/m2 body surface | 963 (337) mg/cycle | NA |
| Dose, median (range) | 150 (12.5–300) mg/day | 20 mg/day | Various | 12 (10–12) mg/m2 body surface | 1000 (375–3000) mg/cycle | NA |
| Patients | ||||||
| Patients receiving treatment, n (%) | 45 (24.2) | 17 (9.1) | 30 (16.1) | 32 (17.2) | 62 (33.3) | 0.002 |
| Age at start, mean (SD), years | 39.2 (13.3) | 34.1 (11.5) | 31.8 (11.9) | 43.5 (14.5) | 44.1 (14.6) | <0.001 |
| Females, n (%) | 41 (91.1) | 16 (94.1) | 25 (83.3) | 24 (75.0) | 51 (82.3) | 0.6 |
| 2006 Wingerchuk criteria fulfilled, n (%) | 33 (73.3) | 14 (82.4) | 29 (96.7) | 25 (78.1) | 48 (77.4) | 0.4 |
| AQP4-ab-positive, n (%) | 39 (86.7) | 11 (64.7) | 27 (90.0) | 28 (87.5) | 54 (87.1) | 0.3 |
Differences between groups tested with χ2 test for rates or analysis of variance for continuous measures.
AQP4-ab, antibodies against aquaporin-4; AZA, azathioprine; GLAT, glatiramer acetate; IFN, interferon-β; Mitox, mitoxantrone; NA, not applicable; RTX, rituximab.